Is the new class of cholesterol drugs the next battleground for payers and prescribers?
With high price tags and a tougher path to generic as a biologic, payer pressure on clinicians to raise adherence for PCSK9 drugs to new heights will be keen.
With high price tags and a tougher path to generic as a biologic, payer pressure on clinicians to raise adherence for PCSK9 drugs to new heights will be keen.
The U.S. healthcare system must expand the network of accountability. Almost all accountability currently lies with physicians.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.